Xavier Santarelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xavier Santarelli has a total of 174 co-authors. Here are the top co-authors by number of shared publications:
Charlotte Cabanne
Bordeaux INP, CBMN, UMR 5248, F-33600 Pessac, France
9 shared publications- Wilfrid Dieryck
Ecole Supérieure de Technologie des Biomolécules de Bordeaux (ESTBB), Université Victor Segalen Bordeaux 2, 146 Rue Léo Saignat, 33076 Bordeaux cedex, France
9 shared publications - Bertrand Garbay
Laboratoire de Biogenèse Membranaire, UMR-CNRS 5544, Université Victor Ségalen Bordeaux 2, France
6 shared publications - Gilles Joucla
Univ. Bordeaux, CNRS, Bordeaux INP, CBMN, UMR 5248, F-33615 Pessac, France
6 shared publications C. Cabanne
IPB, Biotechnologie des Protéines Recombinantes à Visée Santé, EA 4135, F-33000 Bordeaux, France; Univ Bordeaux, Biotechnologie des Protéines Recombinantes à Visée Santé, EA 4135, F-33000 Bordeaux, France
5 shared publicationsA.M Noubhani
Ecole Supérieure de Technologie des Biomolécules de Bordeaux (ESTBB), Université Victor Segalen Bordeaux 2, 146 Rue Léo Saignat, 33076 Bordeaux cedex, France
4 shared publications
Latest Publications
- 1 March 2018
- Published by Elsevier in Journal of Chromatography B
- Vol. 1080, 1-10
Comparative study of strong cation exchangers: Structure-related chromatographic performances
- 1 March 2018
- Published by Elsevier in Journal of Chromatography B
- Vol. 1080, 1-10
Comparative study of strong cation exchangers: Structure-related chromatographic performances
- 3 March 2017
- Published by Wiley
- p. 615-629
PURIFICATION OF IgM and IgA
- Open Access
- 26 January 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (1) , e0170305
A Recombinant Human Anti-Platelet scFv Antibody Produced in Pichia pastoris for Atheroma Targeting
Cells of the innate and adaptive immune system are key factors in the progression of atherosclerotic plaque, leading to plaque instability and rupture, potentially resulting in acute atherothrombotic events such as coronary artery disease, cerebrovascular disease and peripheral arterial disease. Here, we describe the cloning, expression, purification, and immunoreactivity assessment of a recombinant single-chain variable fragment (scFv) derived from a human anti-αIIbβ3 antibody (HuAb) selected to target atheromatous lesions for the presence of platelets. Indeed, platelets within atheroma plaques have been shown to play a role in inflammation, in platelet-leucocyte aggregates and in thrombi formation and might thus be considered relevant biomarkers of atherosclerotic progression. The DNA sequence that encodes the anti-αIIbβ3 TEG4 scFv previously obtained from a phage-display selection on activated platelets, was inserted into the eukaryote vector (pPICZαA) in fusion with a tag sequence encoding 2 cysteines useable for specific probes grafting experiments. The recombinant protein was expressed at high yields in Pichia pastoris (30 mg/L culture). The advantage of P. pastoris as an expression system is the production and secretion of recombinant proteins in the supernatant, ruling out the difficulties encountered when scFv are produced in the cytoplasm of bacteria (low yield, low solubility and reduced affinity). The improved conditions allowed for the recovery of highly purified and biologically active scFv fragments ready to be grafted in a site-directed way to nanoparticles for the imaging of atherosclerotic plaques involving inflammatory processes and thus at high risk of instability.
- 26 January 2017
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (1) , e0170305
Open AccessA Recombinant Human Anti-Platelet scFv Antibody Produced in Pichia pastoris for Atheroma Targeting
Cells of the innate and adaptive immune system are key factors in the progression of atherosclerotic plaque, leading to plaque instability and rupture, potentially resulting in acute atherothrombotic events such as coronary artery disease, cerebrovascular disease and peripheral arterial disease. Here, we describe the cloning, expression, purification, and immunoreactivity assessment of a recombinant single-chain variable fragment (scFv) derived from a human anti-αIIbβ3 antibody (HuAb) selected to target atheromatous lesions for the presence of platelets. Indeed, platelets within atheroma plaques have been shown to play a role in inflammation, in platelet-leucocyte aggregates and in thrombi formation and might thus be considered relevant biomarkers of atherosclerotic progression. The DNA sequence that encodes the anti-αIIbβ3 TEG4 scFv previously obtained from a phage-display selection on activated platelets, was inserted into the eukaryote vector (pPICZαA) in fusion with a tag sequence encoding 2 cysteines useable for specific probes grafting experiments. The recombinant protein was expressed at high yields in Pichia pastoris (30 mg/L culture). The advantage of P. pastoris as an expression system is the production and secretion of recombinant proteins in the supernatant, ruling out the difficulties encountered when scFv are produced in the cytoplasm of bacteria (low yield, low solubility and reduced affinity). The improved conditions allowed for the recovery of highly purified and biologically active scFv fragments ready to be grafted in a site-directed way to nanoparticles for the imaging of atherosclerotic plaques involving inflammatory processes and thus at high risk of instability.
- 2 December 2015
- Published by Wiley in Biotechnology Journal
- Vol. 11 (1) , 117-126
High yield of recombinant human Apolipoprotein A‐I expressed in Pichia pastoris by using mixed‐mode chromatography
A vast majority of the cardioprotective properties exhibited by High‐Density Lipoprotein (HDL) is mediated by its major protein component Apolipoprotein A‐I (ApoA1). In order to develop a simplified bioprocess for producing recombinant human Apolipoprotein A‐I (rhApoA1) in its near‐native form, rhApoA1was expressed without the use of an affinity tag in view of its potential therapeutic applications. Expressed in Pichia pastoris at expression levels of 58.2 mg ApoA1 per litre of culture in a reproducible manner, the target protein was purified by mixed‐mode chromatography using Capto™ MMC ligand with a purity and recovery of 84% and 68%, respectively. ApoA1 purification was scaled up to Mixed‐mode Expanded Bed Adsorption chromatography to establish an 'on‐line' process for the efficient capture of rhApoA1 directly from the P. pastoris expression broth. A polishing step using anion exchange chromatography enabled the recovery of ApoA1 up to 96% purity. Purified ApoA1 was identified and verified by RPLC‐ESI‐Q‐TOF mass spectrometry. This two‐step process would reduce processing times and therefore costs in comparison to the twelve‐step procedure currently used for recovering rhApoA1 from P. pastoris
- 2 December 2015
- Published by Wiley in Biotechnology Journal
- Vol. 11 (1) , 117-126
High yield of recombinant human Apolipoprotein A‐I expressed in Pichia pastoris by using mixed‐mode chromatography
A vast majority of the cardioprotective properties exhibited by High‐Density Lipoprotein (HDL) is mediated by its major protein component Apolipoprotein A‐I (ApoA1). In order to develop a simplified bioprocess for producing recombinant human Apolipoprotein A‐I (rhApoA1) in its near‐native form, rhApoA1was expressed without the use of an affinity tag in view of its potential therapeutic applications. Expressed in Pichia pastoris at expression levels of 58.2 mg ApoA1 per litre of culture in a reproducible manner, the target protein was purified by mixed‐mode chromatography using Capto™ MMC ligand with a purity and recovery of 84% and 68%, respectively. ApoA1 purification was scaled up to Mixed‐mode Expanded Bed Adsorption chromatography to establish an 'on‐line' process for the efficient capture of rhApoA1 directly from the P. pastoris expression broth. A polishing step using anion exchange chromatography enabled the recovery of ApoA1 up to 96% purity. Purified ApoA1 was identified and verified by RPLC‐ESI‐Q‐TOF mass spectrometry. This two‐step process would reduce processing times and therefore costs in comparison to the twelve‐step procedure currently used for recovering rhApoA1 from P. pastoris
- Open Access
- 1 December 2015
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 4, 299-305
Production, in Pichia pastoris, of a recombinant monomeric mapacalcine, a protein with anti-ischemic properties
- 1 December 2015
- Published by Elsevier in Biochemistry and Biophysics Reports
- Vol. 4, 299-305
Open AccessProduction, in Pichia pastoris, of a recombinant monomeric mapacalcine, a protein with anti-ischemic properties
- 1 May 2015
- Published by Elsevier in Journal of Chromatography A
- Vol. 1393, 57-64
Purification process of recombinant monoclonal antibodies with mixed mode chromatography
- 1 May 2015
- Published by Elsevier in Journal of Chromatography A
- Vol. 1393, 57-64
Purification process of recombinant monoclonal antibodies with mixed mode chromatography
- 1 February 2015
- Published by Elsevier in Journal of Biotechnology
- Vol. 195, 89-92
Production and purification of recombinant human hepcidin-25 with authentic N and C-termini
- 1 February 2015
- Published by Elsevier in Journal of Biotechnology
- Vol. 195, 89-92
Production and purification of recombinant human hepcidin-25 with authentic N and C-termini
- 1 January 2015
- Published by Elsevier in Journal of Chromatography B
- Vol. 976-977, 68-77
A comprehensive evaluation of mixed mode interactions of HEA and PPA HyperCel™ chromatographic media
- 1 January 2015
- Published by Elsevier in Journal of Chromatography B
- Vol. 976-977, 68-77
A comprehensive evaluation of mixed mode interactions of HEA and PPA HyperCel™ chromatographic media
- 1 June 2014
- Published by Elsevier in Journal of Chromatography B
- Vol. 960, 209-213
A study on the nature of interactions of mixed-mode ligands HEA and PPA HyperCel using phenylglyoxal modified lysozyme
- 1 June 2014
- Published by Elsevier in Journal of Chromatography B
- Vol. 960, 209-213
A study on the nature of interactions of mixed-mode ligands HEA and PPA HyperCel using phenylglyoxal modified lysozyme
- 17 February 2014
- Published by Springer Nature
- Vol. 1129, 45-51
Media Selection in Ion-Exchange Chromatography in a Single Microplate
High-throughput process development is more and more used in chromatography. Limitations are the tools provided by the manufacturers. Here, we describe a method to select chromatographic media for ion-exchange chromatography using a 96-well filter microplate.
- 17 February 2014
- Published by Springer Nature
- Vol. 1129, 45-51
Media Selection in Ion-Exchange Chromatography in a Single Microplate
High-throughput process development is more and more used in chromatography. Limitations are the tools provided by the manufacturers. Here, we describe a method to select chromatographic media for ion-exchange chromatography using a 96-well filter microplate.